NCT04541368

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells therapy for relapsed multiple myeloma after BCMA CAR-T cells therapy

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for relapsed CS1+ multiple myeloma, the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 50 patients will be enrolled for this trial. Primary objective is to explore the safety, main consideration is dose-related safety.

Conditions

• Relapse Multiple Myeloma

Interventions

Type	Name	Description
DRUG	CS1 Targeted CAR T-cells	Each subject receive CS1 Targeted CAR T-cells by intravenous infusion

Timeline

• Start date: 2020-12-31
• Primary completion: 2023-12-31
• Completion: 2026-12-31
• First posted: 2020-09-09
• Last updated: 2020-12-10

Locations

1 site across 1 country: China